← Leaderboards
Yuesheng Zhang
Johns Hopkins University
$12,984,679
Attributed
$12,984,679
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,984,679 · 9
By mechanism
R01$12,519,111 · 8
R21$465,568 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Thomas W Kensler$20,869,769
- Sandra Guggino$1,833,711
- David K. Ryugo$11,499,012
- Thomas A Kensler$3,946,673
- Sandra E. Guggino$3,361,350
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsSignal TransductionMolecularPlayMalignant NeoplasmsToxic EffectMetabolismCancer CellOverexpressionTumorIn VitroCell LineProteinsCollagenTherapeutic TargetOncogenicMutantBindingChemopreventive AgentMalignant Neoplasm Of Urinary BladderBladderGlucuronosyltransferaseExcretory Function
Grant awards (41)
Targeted Degradation of EGFR and HER2 in NSCLC$499,281
R01 · FY2025 · CA · contact PI
Restore the Tumor-Suppressive Activities of p53 Mutants$398,246
R01 · FY2025 · CA · contact PI
Targeted Degradation of EGFR and HER2 in NSCLC$503,685
R01 · FY2024 · CA · contact PI
Overcoming Drug Resistance in HER2-positive Breast Cancer$443,163
R01 · FY2024 · CA · contact PI
Restore the Tumor-Suppressive Activities of p53 Mutants$341,699
R01 · FY2024 · CA · contact PI
Overcoming Drug Resistance in HER2-positive Breast Cancer$442,064
R01 · FY2023 · CA · contact PI
Restore the Tumor-Suppressive Activities of p53 Mutants$375,169
R01 · FY2023 · CA · contact PI
Overcoming Drug Resistance in HER2-positive Breast Cancer$410,934
R01 · FY2022 · CA · contact PI
Overcoming Drug Resistance in HER2-positive Breast Cancer$551,376
R01 · FY2021 · CA · contact PI
Combating Cetuximab Resistance in Colorectal Cancer$357,421
R01 · FY2021 · CA · contact PI
Combating Cetuximab Resistance in Colorectal Cancer$43,397
R01 · FY2021 · CA · contact PI
Overcoming Drug Resistance in HER2-positive Breast Cancer$450,628
R01 · FY2020 · CA · contact PI
Combating Cetuximab Resistance in Colorectal Cancer$400,747
R01 · FY2020 · CA · contact PI
Combating Cetuximab Resistance in Colorectal Cancer$388,697
R01 · FY2019 · CA · contact PI
Combating Cetuximab Resistance in Colorectal Cancer$400,637
R01 · FY2018 · CA · contact PI
Combating Cetuximab Resistance in Colorectal Cancer$400,566
R01 · FY2017 · CA · contact PI
Gender Disparity in Bladder Cancer and Chemopreventive Intervention$325,312
R01 · FY2017 · CA · contact PI
Gender Disparity in Bladder Cancer and Chemopreventive Intervention$330,992
R01 · FY2016 · CA · contact PI
Gender Disparity in Bladder Cancer and Chemopreventive Intervention$335,821
R01 · FY2015 · CA · contact PI
Gender Disparity in Bladder Cancer and Chemopreventive Intervention$332,723
R01 · FY2014 · CA · contact PI
Gender Disparity in Bladder Cancer and Chemopreventive Intervention$330,482
R01 · FY2013 · CA · contact PI
Bladder Cancer Chemoprevention with Allyl Isothiocyanate$358,798
R01 · FY2011 · CA · contact PI
Novel Dithiolethiones for Bladder Cancer Prevention$310,733
R01 · FY2011 · CA · contact PI
Bladder Cancer Chemoprevention with Allyl Isothiocyanate$360,808
R01 · FY2010 · CA · contact PI
Novel Dithiolethiones for Bladder Cancer Prevention$316,789
R01 · FY2010 · CA · contact PI
Bladder Cancer Chemoprevention with Allyl Isothiocyanate$356,342
R01 · FY2009 · CA · contact PI
Novel Dithiolethiones for Bladder Cancer Prevention$310,084
R01 · FY2009 · CA · contact PI
Bladder Cancer Chemoprevention with Allyl Isothiocyanate$352,007
R01 · FY2008 · CA · contact PI
Novel Dithiolethiones for Bladder Cancer Prevention$298,372
R01 · FY2008 · CA · contact PI
Novel Dithiolethiones for Bladder Cancer Prevention$295,243
R01 · FY2007 · CA · contact PI
Isothiocyanates in the Chemoprevention of Bladder Cancer$206,834
R01 · FY2007 · CA · contact PI
Isothiocyanates in the Chemoprevention of Bladder Cancer$213,012
R01 · FY2006 · CA · contact PI
Prevention of Bladder Cancer with Broccoli Sprouts$234,229
R21 · FY2005 · CA
Isothiocyanates in the Chemoprevention of Bladder Cancer$218,138
R01 · FY2005 · CA
Prevention of Bladder Cancer with Broccoli Sprouts$231,339
R21 · FY2004 · CA
Isothiocyanates in the Chemoprevention of Bladder Cancer$218,138
R01 · FY2004 · CA
Isothiocyanates in the Chemoprevention of Bladder Cancer$215,426
R01 · FY2003 · CA
CANCER CHEMOPREVENTION MECHANISMS OF ISOTHIOCYANATES$142,199
R01 · FY2002 · CA
CANCER CHEMOPREVENTION MECHANISMS OF ISOTHIOCYANATES$138,054
R01 · FY2001 · CA
CANCER CHEMOPREVENTION MECHANISMS OF ISOTHIOCYANATES$82,979
R01 · FY2000 · CA
CANCER CHEMOPREVENTION MECHANISMS OF ISOTHIOCYANATES$62,115
R01 · FY2000 · CA